Alnylam Pharmaceuticals, Inc.

300 Third Street
3rd Floor
Cambridge,  MA  02142-1103

United States
  • Booth: 1354


Alnylam is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of patients who have limited or inadequate treatment options. RNAi therapeutics represent a powerful, clinically-validated approach for the treatment of a wide range of debilitating diseases.